Tag:
Array BioPharma
Latest Headlines
Latest Headlines
Biotech exec settles up on an insider trading case
Back in the spring of 2010, James Lieberman landed a hot biotech stock tip. Unfortunately for him, though, it allegedly came from his boss and concerned his own company--Array BioPharma.
Array shares crater as pain drug disappoints in PhII
Array BioPharma touted its latest mid-stage study of a key pain drug as an unqualified success, beating a placebo and hitting its primary endpoint when tested in patients suffering from osteoarthritis. But when investors dug down into the release and found that its experimental med did no better than a standard treatment, its shares slid more than 11%.
UPDATED: ASCO abstracts reveal added appeal for key cancer drug prospects
The avalanche of ASCO abstracts last night triggered a flurry of news reports about the most notable new data on experimental therapies to be revealed ahead of next month's big meeting in Chicago.
Cancer drug developers angling for center stage at ASCO
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
AstraZeneca flunks Ph2 lung cancer trial with drug from Array BioPharma
Array BioPharma ( $ARRY ) delivered some bad news this morning about one of its experimental cancer drugs. AstraZeneca--which has licensed Array's the drug, selumetinib--came up short in in a mid-stage
Array adds $713M cancer drug pact with Genentech to deal roster
Array BioPharma ($ARRY) has added another high-profile pact to its roster of big-name collaborations. Genentech has stepped in with an upfront payment of $28 million and a promise of up to $685
Array BioPharma axes 70 as it cuts back on discovery work
Boulder, CO-based Array BioPharma is taking the budget axe out to take a chop down its discovery expenses. In a release the biotech said that it is laying off 70 workers--or 20 percent of its
Array shares spike on $467M Novartis cancer pact
Shares of Boulder, CO-based Array BioPharma ( NASDAQ: ARRY ) spiked 33 percent overnight after the developer announced that it had inked a $467 million oncology pact with Novartis. The deal includes a
Amgen delivers $60M upfront for Array diabetes pact
Shares of Array BioPharma ( ARRY ) were amped up overnight by the news that Amgen had committed $60 million upfront, research support and a schedule of unspecified milestones in exchange for the
Array BioPharma shares down on mid-stage RA trial failure
Array BioPharma (ARRY) announced late Thursday that its rheumatoid arthritis drug candidate ARRY-162 was no more effective than a placebo in a mid-stage study. The disappointing results caused the
